Recent News

• 12.08.2025 - HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
• 11.27.2025 - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
• 11.05.2025 - HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
• 11.03.2025 - HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
• 10.23.2025 - HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
• 10.14.2025 - HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Recent Filings

• 12.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.08.2025 - EX-99.1 EX-99.1
• 11.28.2025 - EX-99.1 EX-99.1
• 11.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.05.2025 - EX-99.1 EX-99.1
• 11.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.03.2025 - EX-99.1 EX-99.1
• 10.23.2025 - EX-99.1 EX-99.1
• 10.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]